For what it’s worth, - just over 1.5 M in the bank - recurring...

For what it’s worth,

- just over 1.5 M in the bank
- recurring costs down another 500K on top of the 500 announced in June
- Top 20 still roughly around 45% despite a few large parcels being sold off in the last couple months
- expected revenue of A1.5M for FY19 which I think may be a conservative figure, time will tell.
​

The narrative hasn’t changed much, still developing he sales pipline in both China and NA.
Something to note, which I’m not sure has been mentioned before; ‘Optiscan is pleased to advise that it has received in principle ethics approval from an Australian based hospital for a pilot study of ex-vivo specimens specific to women’s health’

Also worth noting ‘Further details regarding the CZM regulatory pathway will be released as authorised by CZM.’ I’m sure this is the reason the company has been quite vague about specific details surrounding the progression of regulatory approvals.

Barring any more large parcels hitting the market we should see a nice increase in SP,within the next few months, back to where we belong around the 13-15c mark.

ALL IMO PLS DYOR
GC